HIGH

Rising Pharma Carbidopa/Levodopa/Entacapone Tablets Recall 2,064 Bottles Nationwide (2025)

Rising Pharma Holdings recalled 2,064 bottles of Carbidopa, Levodopa and Entacapone tablets distributed nationwide in the United States. Sealed bottles labeled 25 mg/100 mg/200 mg contained 37.5 mg/150 mg/200 mg instead. Healthcare providers and patients should stop using immediately and await recall letter guidance.

Quick Facts at a Glance

Recall Date
October 7, 2025
Hazard Level
HIGH
Brands
Rising Pharma Holdings, Carbidopa, Levodopa and Entacapone
Category
Health & Personal Care
Sold At
Multiple Retailers
Geographic Scope
1 states
At-Risk Groups
GENERAL, PREGNANT

Hazard Information

Product mix up: complaint received that sealed medication bottle contained Carbidopa, Levodopa, and Entacapone film-coated tablets (37.5 mg/150 mg/200 mg) instead of labelled lower strength Carbidopa, Levodopa, and Entacapone film-coated tablets (25 mg/100 mg/200 mg).

What You Should Do

Consumers and healthcare providers should stop using this product immediately. Contact Rising Pharma Holding, Inc. or your healthcare provider for guidance. Notification method: Letter

Get instant alerts for Health & Personal Care recalls

Be the first to know. Free instant alerts to your inbox.

No spamUnsubscribe anytime

About This Product

Carbidopa/Levodopa/Entacapone is a fixed-dose combination used to manage Parkinson’s disease symptoms by replenishing dopamine. The triple therapy requires precise dosing to balance efficacy and side effects.

Why This Is Dangerous

A product mix-up that changes tablet strength can lead to overdosing or underdosing, potentially causing adverse reactions or reduced symptom control.

Industry Context

This recall is not described as part of a broader industry pattern.

Real-World Impact

Patients may experience unexpected side effects or loss of disease control. The recall could require provider intervention and possible medication changes.

Practical Guidance

How to identify if yours is affected

  1. Verify NDC 16571-691-01 on the bottle.
  2. Check Lot CS25070 and expiration date 03/31/2027.
  3. Confirm bottle size is 100-count.

Where to find product info

NDC, lot number and expiration are on the bottle label and carton.

What timeline to expect

Replacement or refund guidance will be provided in the recall letter; processing typically 4-8 weeks.

If the manufacturer is unresponsive

  • Document all communications with Rising Pharma and your provider.
  • File a consumer complaint with FDA if there is no progress.

How to prevent similar issues

  • Always verify NDC and strength before dispensing or taking a medication.
  • Ask pharmacists for confirmation if there is any packaging discrepancy.
  • Keep a personal medicine list with current dosages and cross-check during supply changes.

Documentation advice

Keep the recall letter, bottle, and any prescription records; photograph labels and packaging for records.

Product Details

NDC: 16571-691-01 Lot #: CS25070 Exp: 03/31/2027 Size: 100-count bottle Sold: Nationwide in the USA Manufacturer: Suven Pharmaceuticals Limited, Pashamylaram, Telangana 205307, India Distributed for: Rising Pharma Holdings, East Brunswick, NJ 08816 Quantity: 2,064 bottles Price: Unknown

Reported Incidents

No injuries or incidents have been reported.

Key Facts

  • 2064 bottles recalled nationwide
  • NDC 16571-691-01
  • Lot CS25070
  • Exp 03/31/2027
  • Mislabeled strength 25 mg/100 mg/200 mg vs actual 37.5 mg/150 mg/200 mg
  • Class II recall, HIGH hazard level, Recall date 2025-10-07

Safety Guide

Not sure what to do next? Our guide walks you through the process step by step.

Read: What to Do When You Find a Recalled Product

Get Alerts for Health & Personal Care Recalls

Get instant alerts for recalls that affect you. Free forever.

Safety Assessment

Risk LevelHIGH
Severity Score
7/ 10
Affected Groups
GENERALPREGNANT
Injury Types
POISONING

Product Details

Model Numbers
Lot CS25070
exp. date 03/31/2027
UPC Codes
16571-689
16571-690
16571-691
+9 more
Affected States
ALL
Report Date
October 22, 2025
Source Agency
FDA - Drug Safety
Recall Status
ACTIVE

Related Recalls

Vehicles & Parts
HIGH

Mazda CX-70 Recall 2025 for Powertrain Control Module Software May Lose Drive Power

Mazda North American Operations is recalling 2024 CX-90 and 2025 CX-70 SUVs sold through Mazda dealers. The PCM and ECM software can illuminate malfunction indicator lights and cause a loss of drive power, increasing crash risk. Owner notification letters were mailed December 19, 2024, and Mazda will reprogram the PCM and ECM at no charge.

Mazda
Loss of
Read more
Vehicles & Parts
HIGH

Nissan Kicks 2025 Certification Label Recall for GVWR/GAWR Errors (PD136, PMA47)

Nissan North America is recalling certain 2025 Nissan Kicks vehicles sold through Nissan dealers nationwide. The certification label may print incorrect GVWR and GAWR values, risking overload. Some SR trims with a 19-inch wheel package may display an incorrect wheel size on the label, and owners should contact their Nissan dealer to arrange replacement labels.

Nissan
An overloaded
Read more